Drug intelligence / Profile preview

VV119

Development stage: Phase 2
Lead developer: Vigonvita Life Sciences
Modality: Small Molecules
Administration: Oral

Overview

VV119 is an orally bioavailable small molecule drug under development by Vigonvita Life Sciences for the treatment of schizophrenia. It is currently in Phase 1 clinical trials to evaluate its safety, tolerability, pharmacokinetics, and preliminary efficacy in both healthy volunteers and patients with schizophrenia. The precise mechanism of action has not been defined or disclosed as of the latest updates. VV119 is classified as a new molecular entity and belongs to the antipsychotic class.

Targets

HTR3A (5-hydroxytryptamine receptor 3A)DRD (Dopamine receptors)

Beyond the preview

Go deeper on VV119.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on VV119.

Explore the full profile